Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States
Teshamae Monteith, Jessica Cirillo, Karina Nakajima, Martine C. Maculaitis, Elizabeth McCaig, Nemin Chen, Lucy Abraham, Meghan Fajardo, Feng Dai, Jessica Ailani · 2026
Read Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States by Teshamae Monteith, Jessica Cirillo, Karina Nakajima, Martine C. Maculaitis, Elizabeth McCaig, Nemin Chen, Lucy Abraham, Meghan Fajardo, Feng Dai, Jessica Ailani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13645540.txt.
Description
Teshamae Monteith and nine colleagues report a United States survey study on sex differences in short-term use of the migraine drug rimegepant. Short-term prevention means taking a drug for a limited stretch when attacks are more likely. The team gathered real-world answers online from adults who had used the drug recently. Their focus is how women and men differ in triggers and in reasons for choosing this approach.
Of 425 adults surveyed, 152 used rimegepant for short-term prevention, and most users were women, who more often cited a doctor's advice, attack frequency, and attack severity as reasons. Stress, poor sleep, and noise were the leading triggers for both sexes. Satisfaction ran high across the group, which the authors read as support for this flexible way of preventing attacks.
Catalog record
| CREATOR | Teshamae Monteith, Jessica Cirillo, Karina Nakajima, Martine C. Maculaitis, Elizabeth McCaig, Nemin Chen, Lucy Abraham, Meghan Fajardo, Feng Dai, Jessica Ailani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |